Testing Treatment for Prostate Cancer
common.study.values.description
“A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer”
The purpose of this study is to establish the recommended phase 2 dose (RP2D) of niraparib combination therapies of Part 1 and to evaluate the antitumor activity and safety of niraparib combination therapies of Part 2.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Niraparib 200 mg
Participant will receive niraparib 200 mg orally once daily.
Drug - Cetrelimab mg
Participants will receive cetrelimab 240 mg IV every 2 weeks.
Drug - Cetrelimab 480 mg
Participants will receive cetrelimab 480 mg IV every 4 weeks.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
common.study.values.clinical-trial-id
NCT03431350
participant.views.study.view.id
lejoBa
